**SUSPENDED** ALLIANCE A011104  Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer (Feig)

UCI 15-83  Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging in a Multi-Center Setting (Tromberg)

UCI 10-39  Predicting Pathological Response within the First Week of Neoadjuvant Chemotherapy Using Functional Parameters Measured with Diffuse Optical Spectroscopic Imaging (DOSI) (Tromberg)

UCI 11-15  Correlation of Clinical and MRI Findings with Prognosis of Breast Cancer Patients (Su)

UCI 11-21  Analysis of Imaging Features of Breast Diseases and Breast Density Evaluated on Mammogram, Ultrasound & MRI Collected in a Database (Su)

UCI 14-86  Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System (Su)

UCI 14-85  Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System (Su)

UCI 16-23  Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer [The WISDOM Study (Women Informed to Screen Depending On Measures of Risk)] (Anton-Culver)

**SCREENING / DIAGNOSTIC / EPIDEMIOLOGIC / INTERVENTIONAL**

**BREAST CANCER**

**CORRELATIVE / OBSERVATIONAL**

UCI 95-29  Measurement of Breast Tissue Optical Properties (Tromberg)

UCI 10-24  ATHENA Breast Health Network (Anton-Culver)

UCI 12-10  Development of a Quantitative Tissue Optical Index of Breast Density for Prediction of Hormone Therapy Response (O'Sullivan)

UCI 13-19  Registry Study of Patients Treated with Neoadjuvant Chemotherapy Followed by Mastectomy in Stage I, II, III BREAST CANCER (Daroui)

UCI 14-25  Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)

UCI 14-62  Breast Tumor Oxygenation during Exercise (Tromberg)

UCI 14-81  Mi Salud, Mi Vida: A Self-Discovery Tool for Latina Breast Cancer Survivors (Sorkin)

UCI 15-64  A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-Conserving Surgery (Police)

UCI 16-01  Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) (Nelson)

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

**opening soon**
Breast Cancer Therapeutic Clinical Trials

**Breast Cancer**

**Neo-Adjuvant**

**Adjuvant**

**Multiple Disease Sites**

**UCI 17-50**
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)

**Stage I-III**

**UCI 14-67**
A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel with Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting (Mehta)

**HER2+ High Risk**

**SWOG S1207**
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer (Mehta)

**SWOG S1418**
Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy (Mehta)

**ALLIANCE A011502**
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial (Mehta)

**Hormone+ High Risk**

**NSABP B51**
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (Darouei)

For more details contact 1-877-UC-STUDY or ucsstudy@uci.edu

**opening soon**

1117
Breast Cancer Therapeutic Clinical Trials

**Advanced**

**UCI 17-45** COMPLEEMENT-1: An Open-Label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination with Letrozole for the Treatment of Men and Pre/Postmenopausal Women with Hormone Receptor-Positive (HR+) HER2-Negative (HER2-) Advanced Breast Cancer (aBC) with No Prior Hormonal Therapy for Advanced Disease (Parajuli)

**Metastatic**

**Targeted therapy**

**ECOG EAY131** Molecular Analysis for Therapy Choice (MATCH) (Bota)

**SWOG S1609** DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)

**NRG BR002** A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer (Daroui)

**UCI 16-74** A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine (Carrillo)

**NSABP FB-10** A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) with Neratinib in Women with Metastatic HER2-Positive Breast Cancer (Parajuli)

**UCI 17-79** Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (Parajuli)

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu

**opening soon**

1117